Kona Community Hospital Pharmacy (Hawaii Health Systems Corporation), Kealakekua, HI
Is Kona Community Hospital Pharmacy (Hawaii Health Systems Corporation) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Kona Community Hospital Pharmacy (Hawaii Health Systems Corporation) hold a Hawaii pharmacy license?
State board of pharmacy records for Hawaii are not checked: this index has not yet added that board’s records.
Has Kona Community Hospital Pharmacy (Hawaii Health Systems Corporation) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Feb 1, 2021), 1 warning letter close-out (Jun 27, 2022), 1 state handoff letter (Jun 27, 2022) and 1 FMD-145 letter (Jun 27, 2022) for Kona Community Hospital Pharmacy (Hawaii Health Systems Corporation). State board of pharmacy records for Hawaii are not checked: this index has not yet added that board’s records. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Hawaii Health Systems Corporation; Kona Community Hospital Pharmacy
- Location
- Kealakekua, HI
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jun 27, 2022
- FDA Data Dashboard inspections
- 1 inspection: 1 NAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hawaii Health Systems Corporation, (dba Kona Community Hospital Pharmacy), a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Jun 27, 2022 | Warning letter close-out | Warning Letter Close Out Issued 06/27/2022 | Not linked by FDA |
| Jun 27, 2022 | State handoff letter | State Handoff Letter Issued 06/27/2022 | Not linked by FDA |
| Jun 27, 2022 | FMD-145 letter | FMD-145 Letter Issued 06/27/2022 | Not linked by FDA |
| Feb 1, 2021 | Warning letter | Warning Letter (02/01/2021) | FDA copy (archived) |
| Dec 13, 2019 | Form 483 | 483 Issued 12/13/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Hawaii Health Systems Corporation, Kealakekua, HI (FEI number 3006684882), matched to this page by exact name, city and state. It lists 1 inspection: 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 28, 2022 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3006684882 | 1164945 |
Form 483s FDA has published for this site
- Dec 13, 2019: Form 483 to Hawaii Health Systems Corporation, published Feb 4, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Dec 2, 2019 to Dec 13, 2019: 8 observations
- Firm on the cover
- Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy, 79-1019 Haukapila Street, Kealakekua, HI 96750
- FEI number
- 3006684882
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 1201 Harbor Bay Parkway Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Specifically, actionable microbial contamination was discovered inside the ISO 5 aseptic processing environments during <Redacted B4> cleanroom certifications and no evaluation of product impact was made. For example:
a.) During the 12/11/18 <Redacted B4> recertification, the ISO 5 Hazardous Drug Room Biological Safety Cabinet (BSC) Surface Sample, <Redacted B4> had one mold colony isolated on the bacterial plate. The mold was not identified. The firm did not evaluate any products filled in the ISO 5 BSC on 12/11/18 for product impact, including but not limited to: Azacitidine 150mg.
b.) On the 01/24/19 retest the ISO 5 Non-Hazardous Dmg Room Laminar Airflow (LAF) Hood Viable Air Sample, ID <Redacted B4> had a calculated 4 colony forming units (cfu) /m3 , which was deemed acceptable in the report. ...
Observation 2
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.
Specifically, actionable microbial contamination was discovered inside <Redacted B4> rooms, where the ISO 5 Biological Safety Cabinet (BSC) and ISO 5 Laminar Airflow (LAF) Hood are located, during <Redacted B4> cleanroom certifications and periodic settling plate samples and no evaluation of product impact was made. For example:
a.) Duringthe 12/11/18 <Redacted B4> recertification, the ISO 7 Non-Hazardous Drug Room Viable Air Sample, ID <Redacted B4> had a calculated 44 colony forming units (cfu) /m3 identified as Coagulase-negative Staphylococcus species, Dermabacter hominis, and Micrococcus luteus, and the ISO 7 Hazardous Drug Room Viable Air Sample, ID <Redacted B4> had a calculated 18 cfu/m3 identified as Bacillus species, Micrococcus luteus, Micrococcus species, anaStaphylococcus haemolyticus. ...
Observation 3
Your facility design allowed the influx of poor quality air into a higher classified area.
Specifically, the air balance between rooms is not controlled to ensure cascading flow of air between areas of lesser classifications. For example:
a.) The <Redacted B4> area"'does not seal completely when the doors on either sicle of <Redacted B4>. The ISO 7 Hazardous Drug Room is maintained at a negative pressure relative to adjacent spaces, allowing air from the unclassified area to continuously enter the room. The differential pressure between the ISO 7 Hazardous Drug Room and the unclassified office area is not monitored. Additionally, during the transfer of finished sterile hazardous drugs, we observed <Redacted B4> open at the same time. The ISO 7 Hazardous Drug Room contains the ISO 5 Biosafety Cabinet, which is used in the production of sterile hazardous drug products, including but not limited to Leucovoin, Oxaliplatin, Fluorouracil, Gemcitabine, and Cisplatin.
,-.J
c.) The air pressure differential between the ISO 7 Non-Hazardous Drug Room and the ISO 8 Ante Room has been below and above the specified range of <Redacted B4> " w.c. ...
Observation 4
Your facility was designed and/or operated in a way that permits poor flow of personnel and materials.
b.) HEPA filtered air supply vents and air returns are all located on the ceilings of the ISO 7 Hazardous Drug Room, ISO 7 Non-Hazardous Drug Room, and ISO 8 Ante Room. The metal air vents are not designed to provide unidirectional air to the rooms with air dispersing in two to four different directions from each vent. The firm has not evaluated the air patterns in each room.
c.) The ISO 7 Hazardous Drug Room, ISO 7 Non-Hazardous Drug Room, and ISO 8 Ante Room share air handling units @ <Redacted B4> and a common final HEPA filter with the unclassified office area of the pharmacy. There are no HEPA filters located directly at the air supply vents to each ISO classified room.
d.) Operators entering the ISO 7 Hazardous Drug Room must first enter the ISO 8 Ante Room to perform initial gowning and pass through the ISO 7 Non-Hazardous Drug Room to enter the ISO 7 Hazardous Drug Room, where additional gowning and gloves are donned. ...
Observation 5
The segregated production areas sun ounding the ISO 5 classified aseptic processing area contained dust-collecting overhangs without adequate and frequent cleaning.
Specifically, apparent dust-like residue was observed on a sterile wipe after wiping the crevices of the metal HEPA-filtered air supply vents in the ISO 7 Non-Hazardous Drug Room and ISO 8 Ante Room. These rooms share the same HEPA-filtered air supply that also goes to the ISO 7 Hazardous Drug Room and unclassified office area. The metal vent located closest to the ISO-classified areas located in the unclassified office area also showed apparent dust-like residue after wiping the crevices with a sterile wipe.
Observation 6
HEP A filters were not sealed around each perimeter to the suppori frame.
Specifically, the firm's cleanroom certification reports indicate the room supply HEPA filters are not leak tested in the ISO 7 Hazardous Drug Room, ISO 7 Non-Hazardous Drug Room, and ISO 8 Ante Room because the filters in the housing are not clamped down. On 12/04/19, the Pharmacy Director indicated she did not believe the HEPA filters have ever been leak tested. The ISO 7 Hazardous Drug Room contains the ISO 5 BSC, which is used in the production of sterile hazar·dous drug products. The ISO 7 Non-Hazardous Drug Room contains the ISO 5 LAF Hood, which is used in the production of sterile non-hazardous drug products. The ISO 8 Ante Room is used by operators performing production operations to don sterile garbing materials prior to entering one of the ISO 7 areas and the Ante Room is also used for storage of materials used for production operations.
The edges of the air inlet metal vents installed in the ceilings of the ISO 7 Hazardous Drug Room, ISO 7 Non-Hazardous Drug Room, and ISO 8 Ante Room are not sealed to the ceilings of the rooms.
Observation 7
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Observation 8
Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, non-sterile <Redacted B4> is a disinfectant used for daily cleaning of the ISO 5 Laminar Airflow (LAF) Hood and ISO 5 Biological Safety Cabinet (BSC) surfaces, which the film uses in the production of sterile injectable drug products.
State board of pharmacy records
State board of pharmacy records for Hawaii are not checked: this index has not yet added that board’s records.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.